{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-020343","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.668933+00:00","generated_at":"2026-06-20T05:36:27.136152+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Taysha receives FDA feedback on TSHA-120 GAN; sets Rett syndrome milestones for 2023","bullets":["FDA acknowledged MFM32 as acceptable endpoint; recommended double-blind placebo-controlled design for TSHA-120 BLA.","Dosing of first adult Rett patient with TSHA-102 expected H1 2023; initial clinical data also in H1 2023.","CTA submission to UK MHRA for pediatric Rett syndrome expected mid-2023; IND to FDA planned H2 2023.","Operational, structural and personnel changes implemented following business review to enhance execution."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-020343","json":"https://secwatch.observer/filing/0001193125-23-020343.json","markdown":"https://secwatch.observer/filing/0001193125-23-020343.md","text":"https://secwatch.observer/filing/0001193125-23-020343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523020343/0001193125-23-020343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523020343/d427060d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T05:36:27.136152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}